Why the study?
Significant progress has been made in understanding the multifactorial mechanisms contributing to heart failure in diabetes since diabetic cardiomyopathy was first described.
This review provides a comprehensive overview of the mechanisms underlying diabetic cardiomyopathy and the impact of antidiabetic therapies on heart failure.
Synthesizes diabetic cardiomyopathy mechanisms and therapy effects; hypothesis-generating without altering clinical practice.
Diabetic cardiomyopathy is a complex condition characterized by structural and functional changes in the heart, which are not explained by other known cardiovascular risk factors in patients with diabetes. Since Rubler first described this condition in 1972, there has been significant progress in understanding the multifactorial mechanisms that contribute to the development and progression of heart failure in diabetic patients. In this review, we provide a comprehensive discussion of the key mechanisms that underlie the development of diabetic cardiomyopathy, including chronic hyperglycemia, autonomic neuropathy, altered substrate utilization, and dysregulated insulin pathways. We also compare the distinct characteristics of heart failure in type 1 and type 2 diabetes and review the effects of antidiabetic medications on heart failure in diabetic patients with a particular emphasis on ongoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Mann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: